Allogene Therapeutics (ALLO) Return on Capital Employed (2018 - 2026)

Allogene Therapeutics has disclosed Return on Capital Employed across 9 years of filings, most recently posting 50.37% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 50.37%, up 358.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 50.37% (up 358.0% YoY), and the FY2025 annual result was 46.54%, up 223.0% from the prior year.
• Return on Capital Employed came in at 50.37% for Q1 2026 at Allogene Therapeutics, up from 52.95% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 23.22% in Q1 2022 to a low of 55.57% in Q2 2025.
• The 5-year median for Return on Capital Employed is 50.71% (2023), against an average of 46.21%.
• Across the five-year window, Return on Capital Employed plunged 2560 bps in 2023 and jumped 358 bps in 2026, its largest moves.
• Allogene Therapeutics' Return on Capital Employed stood at 41.72% in 2022, then slipped by 23 bps to 51.13% in 2023, then dropped by 0 bps to 51.22% in 2024, then dropped by 3 bps to 52.95% in 2025, then rose by 5 bps to 50.37% in 2026.
• The last three Return on Capital Employed figures came in at 50.37% (Q1 2026), 52.95% (Q4 2025), and 53.71% (Q3 2025), per Business Quant data.